CliffBio
biologic

Zevalin

ibritumomab tiuxetan

Loss of exclusivityFebruary 2014projected — 12-year biologic exclusivity estimate
CompanyAcrotech Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameZevalin
Active ingredientibritumomab tiuxetan
Strength3.2MG/2ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2002
Marketing statusRx

More from Acrotech Biopharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Zevalin patent cliff — loss of exclusivity February 2014 | CliffBio